NASDAQ$ABEO
Abeona Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Abeona Therapeutics Inc reported net income of $108.8 million for Q2 2025 driven by the gain on sale of its priority review voucher.
The company received FDA approval for ZEVASKYN in April 2025 and sold its priority review voucher for gross proceeds of $155 million, recognizing a $152.4 million gain. This resulted in strong net income despite continued operating losses from R&D and pre-commercial activities. Cash and cash equivalents increased significantly to $163.5 million as the company prepares for commercial launch.
- FDA approved ZEVASKYN for treatment of RDEB wounds on April 28, 2025.
- Sold priority review voucher for $155 million gross proceeds, generating $152.4 million net gain.
- Q2 net income reached $108.8 million compared to $7.4 million in the prior year quarter.
- Ended quarter with $163.5 million in cash and cash equivalents to support commercial launch.
Headline financials
Revenue & EPS history
Abeona Therapeutics · Revenue · Quarterly
$400K
Forward guidance
Company plans to initiate commercial sales of ZEVASKYN through qualified treatment centers beginning in Q3 2025.
Tailwinds
- Strong cash position following PRV sale supports launch activities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-0.3%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+6.4%
Avg return
30 days after
44%
27 / 62 earnings
Positive
+18.8%
Q3 2025
Best reaction
-28.9%
Q1 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +0.7% | -5.5% | -2.8% | |
| Q4 2025 | +6.1% | -10.1% | +8.7% | |
| Q3 2025 | +18.8% | +8.2% | +28.5% | |
| Q1 2025 | -4.2% | -2.8% | -8.1% | |
| Q4 2024 | -1.2% | -3.8% | -6.9% | |
| Q3 2024 | -3.9% | -3.4% | -3.4% | |
| Q2 2024 | +12.7% | +13.1% | +26.5% | |
| Q1 2024 | +9.5% | +6.0% | +8.8% | |
| Q4 2023 | -12.3% | -11.8% | -8.1% | |
| Q3 2023 | +3.9% | +2.4% | +15.4% | |
| Q2 2023 | +0.7% | +0.3% | +34.6% | |
| Q1 2023 | -7.2% | -5.3% | +32.8% | |
| Q4 2022 | +1.8% | +1.8% | +10.4% | |
| Q3 2022 | -8.0% | -8.0% | -32.3% | |
| Q2 2022 | +6.5% | +14.7% | -5.8% | |
| Q1 2022 | +12.5% | +0.0% | +6.3% | |
| Q4 2021 | +3.2% | +9.7% | -32.3% | |
| Q3 2021 | -5.4% | -19.6% | -43.5% | |
| Q2 2021 | -0.8% | +3.2% | +4.8% | |
| Q1 2021 | +6.5% | +6.5% | +9.0% | |
| Q4 2020 | -1.1% | -5.8% | -14.7% | |
| Q3 2020 | +11.7% | +24.3% | +41.7% | |
| Q2 2020 | +1.7% | -3.8% | -29.0% | |
| Q1 2020 | -7.2% | +29.1% | +16.3% | |
| Q4 2019 | +17.2% | +22.4% | +43.7% | |
| Q3 2019 | -6.4% | -6.8% | +60.2% | |
| Q2 2019 | +0.0% | +6.6% | +30.7% | |
| Q1 2019 | -8.2% | -3.0% | -29.3% | |
| Q4 2018 | -2.0% | -7.2% | +1.0% | |
| Q3 2018 | -22.0% | -24.1% | -13.6% | |
| Q2 2018 | -7.1% | -11.6% | -7.1% | |
| Q1 2018 | +10.9% | +11.4% | -13.8% | |
| Q4 2017 | -9.3% | -4.7% | +17.3% | |
| Q3 2017 | +6.6% | -2.6% | +9.3% | |
| Q2 2017 | +14.9% | +5.4% | +89.2% | |
| Q1 2017 | -1.6% | -1.6% | -20.8% | |
| Q4 2016 | +2.0% | +3.0% | +13.0% | |
| Q3 2016 | +5.7% | +18.0% | -15.6% | |
| Q2 2016 | +4.3% | +5.9% | +27.1% | |
| Q1 2016 | +4.1% | — | — | |
| Q4 2015 | -5.0% | — | — | |
| Q3 2015 | +1.8% | — | — | |
| Q2 2015 | -3.9% | — | — | |
| Q1 2015 | -7.2% | — | — | |
| Q2 2014 | -3.2% | — | — | |
| Q4 2014 | -3.2% | — | — | |
| Q3 2014 | -8.5% | — | — | |
| Q1 2014 | +13.6% | — | — | |
| Q2 2013 | -10.3% | — | — | |
| Q4 2013 | -10.3% | — | — | |
| Q3 2013 | -6.3% | — | — | |
| Q1 2013 | +2.2% | — | — | |
| Q4 2012 | -8.3% | — | — | |
| Q3 2012 | -7.4% | — | — | |
| Q2 2012 | +6.5% | — | — | |
| Q1 2011 | -28.9% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +13.9% | — | — | |
| Q2 2011 | -4.4% | — | — | |
| Q2 2010 | -4.4% | — | — | |
| Q4 2010 | -0.9% | — | — | |
| Q3 2010 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro